Despite ICB showed excellent cancer therapy effects, and some inhibitors including anti-CTLA-4 and PD-L1 monoclonal antibodies have been approved by FDA, however, some limitations still exist such as high off-target, low objective response rate and the risk of immune-related side effects (152). Here, CTLA4 is linked to cancer.